Should also consider that as China,Brazil,India and South East...

Should also consider that as China,Brazil,India and South East Asia develop and more people join their middle class along with food,housing,consumables etc health issues will begin to be addressed.

HCV infection rates in these countries dwarf the US and Europe.The demand for pharmaceuticals in the developing world will explode.

The premiums being paid for a foothold in the HCV markets appear expensive when framed by the US and European Markets.

However include the increasing middle class masses from China especially and it all begins to make sense.They can now afford health care!!!!


Interferon and Ribavirin are not disappearing any time soon as a standard of care in these developing nations due to their relative affordability.Biotron mentioned this in a recent presentation.Bit225 is as relevant as ever.

Just as the markets for commodities have increased on an unprecedented scale so will the market for pharmaceuticals and there is no bigger market than the hepatitis market.